[Strategic Guide] Establishing Corporate Liability For Inadequate Post-Market Surveillance
#Strategic #Guide #Establishing #Corporate #Liability #Inadequate #PostMarket #SurveillanceWebinar How to set up post-market surveillance for your medical device by Let's Talk Risk
Title: Webinar How to set up post-market surveillance for your medical device
Channel: Let's Talk Risk
[Tech Breakdown] Fetal Acidosis: How Blood Gas Analysis (Ph Levels) Establishes Hypoxic Duration
[Strategic Guide] Establishing Corporate Liability For Inadequate Post-Market Surveillance
The Quiet Crisis of Post-Market Surveillance
I remember sitting in a windowless conference room in 2018, surrounded by stacks of red-welded banker’s boxes, drinking lukewarm coffee that tasted like burnt paper. My team was reviewing the internal engineering logs of a mid-sized orthopedic manufacturer whose hip implant was failing at three times the industry-standard rate. What struck me wasn’t a sudden, dramatic "aha!" moment of malicious intent. Instead, it was the suffocating presence of corporate apathy. Thousands of pages of patient complaints, surgeon emails, and field sales reports had been systematically filed away under a generic "monitoring" code, left to gather digital dust while the marketing department continued to push the device as "life-changing."
This is the quiet crisis of post-market surveillance (PMS) in the medical device and pharmaceutical industries. For decades, manufacturers have treated the post-market phase as a regulatory tax—a tedious, administrative chore to be completed with the minimum possible effort. They pour hundreds of millions of dollars into pre-market clinical trials, regulatory approvals, and flashy launch campaigns, only to hand the keys of safety monitoring to understaffed, entry-level quality departments. This structural imbalance creates a dangerous blind spot where early safety signals are missed, ignored, or actively suppressed until the body count—or the litigation class—becomes too large to ignore.
To understand why this happens, we must look at the psychological landscape of corporate risk management. When a device is cleared or approved by regulatory bodies like the FDA, a dangerous cognitive bias takes hold within the C-suite. Executives begin to treat regulatory clearance not as a baseline, but as an absolute shield of safety. They fall into the trap of believing that because a product met the threshold for market entry, any subsequent failures are anomalous, user-related, or simply the unavoidable cost of doing business. This mindset breeds a culture of passive compliance, where the goal of PMS is not to find problems, but to document that no problems were officially "confirmed" according to highly restrictive, self-serving internal definitions.
The reality, of course, is that pre-market testing is fundamentally limited. No clinical trial, no matter how well-designed, can replicate the chaotic, diverse, and long-term environment of the real world. Once a product is distributed to hundreds of thousands of patients with varying comorbidities, lifestyles, and surgical techniques, the true risk profile of the device begins to emerge. Post-market surveillance is the only mechanism capable of capturing this reality. When a corporation fails to maintain an active, scientifically rigorous PMS system, they are not just violating regulatory standards; they are conducting an uncontrolled, unconsented experiment on the public.
The Legal Anatomy of Inadequate PMS
When we peel back the layers of a product liability lawsuit, we find that establishing liability for inadequate post-market surveillance requires a fundamental shift in how we conceptualize corporate negligence. Traditionally, plaintiffs' attorneys focus heavily on design defects or manufacturing defects. While these claims are vital, they are often difficult to prove and highly susceptible to technical, expert-driven defense strategies. In contrast, a claim centered on post-market surveillance focuses on the company’s behavior after the product left the factory floor. It asks a simple, devastating question: What did the company know, when did they know it, and what did they choose to do about it?
In the eyes of the law, a manufacturer's duty to warn is not a static obligation frozen at the moment of sale; it is a continuous, evolving duty. Under the Restatement (Third) of Torts: Products Liability, a seller is subject to liability for harm caused by a failure to warn if, after manufacture, the seller knows or reasonably should know that the product poses a substantial risk of harm to persons or property. This continuous duty is the legal bedrock upon which PMS liability is built. If a company fails to set up a system capable of learning about these risks, they cannot use their own self-inflicted ignorance as a defense against a failure-to-warn claim.
Negligence in this context is often characterized by a systematic failure to act as a reasonably prudent manufacturer. A prudent manufacturer does not wait for a regulatory agency to force their hand; they actively hunt for safety signals. When a plaintiff can demonstrate that the manufacturer’s PMS system was so poorly designed, underfunded, or ignored that it was functionally incapable of detecting a clear safety trend, the nature of the case changes. It transitions from a dispute over complex biomechanical engineering to a straightforward story of corporate negligence and the breach of a fundamental safety promise.
Furthermore, this failure frequently intersects with claims of fraud by omission or negligent misrepresentation. When a company continues to market a device as safe and effective while possessing unanalyzed, raw data that suggests the opposite, they are actively misleading the medical community. The legal strategy here involves tying the regulatory violations—such as failing to report adverse events under 21 CFR Part 803—directly to the common-law duty of care. By showing that the regulatory violations were the direct cause of the informational gap that injured the plaintiff, we establish a robust, multi-layered framework for liability.
The Regulatory Baseline: FDA, MDR, and the Illusion of Compliance
To successfully litigate these cases, one must become intimately familiar with the regulatory frameworks that govern post-market activities. In the United States, the FDA lays down strict rules under 21 CFR Part 820 (specifically 820.198 for complaint files) and 21 CFR Part 803 (Medical Device Reporting). These are not mere suggestions; they are federal mandates. However, many corporations have mastered the art of "paper compliance." They establish beautiful, written Standard Operating Procedures (SOPs) that look pristine on paper during an FDA audit, but are completely divorced from the day-to-day operations of the engineering and clinical teams.
Across the Atlantic, the European Union’s Medical Device Regulation (EU MDR 2017/745) has raised the bar significantly, establishing what is currently the global gold standard for post-market vigilance. Under Annex III of the EU MDR, manufacturers must implement a proactive, systematic Post-Market Surveillance system that is integral to the device’s quality management system. Unlike the historically reactive US system—which often relies on doctors voluntarily reporting issues—the EU MDR demands active Post-Market Clinical Follow-up (PMCF). This requires manufacturers to proactively collect and evaluate clinical data from the use of their devices in real-world clinical settings over their entire expected lifetime.
+-----------------------------------------------------------------------------+
| PRO-TIP |
| Do not let defense counsel convince the court that compliance with FDA's |
| passive reporting standards (MAUDE) satisfies their common-law duty of |
| care. Always contrast the passive collection of complaints with the active |
| clinical follow-up required by modern global standards like the EU MDR. |
| Show that the technology and methodologies for active surveillance were |
| readily available to the defendant, yet they chose the cheaper, passive path.|
+-----------------------------------------------------------------------------+
This divergence between passive and active surveillance is where corporate liability often crystallizes. A company operating globally will often maintain two different standards of care: a highly rigorous, proactive PMCF system for their European market, and a lax, passive system for the United States. When you find a manufacturer that is actively tracking and identifying safety signals in Germany or France, but ignoring those same signals in Ohio or Texas because the FDA's passive MAUDE database didn't flag them, you have uncovered a devastating narrative of double standards. This is not just regulatory non-compliance; it is a conscious decision to subject American patients to a lower standard of safety.
Ultimately, the defense will always beat the drum of "we complied with all regulatory requirements." Your job is to dismantle this illusion of compliance. You must show that regulatory regulations represent the floor, not the ceiling, of a manufacturer's duty to protect patients. Compliance with the letter of an FDA regulation does not insulate a company from liability if they knew, through other channels, that their product was harming people. By comparing their internal actions against both domestic regulations and international standards, you can expose the gap between regulatory box-checking and genuine patient safety.
The Threshold of Actionable Knowledge
At what precise moment does a collection of scattered data points transform into a legal obligation to act? This is the battleground of "actionable knowledge." In product liability litigation, the defense will argue that early reports of device failure were merely "anecdotal," "confounded by patient comorbidities," or "within the expected failure rate." They will claim they did not have "scientific certainty" of a defect, and therefore had no duty to warn or recall. This argument is a rhetorical sleight of hand designed to confuse the jury. The law does not require scientific certainty; it requires a reasonable appreciation of a risk.
To establish constructive knowledge—the standard of what a company should have known—you must reconstruct their data inflows. A modern medical device manufacturer receives information from an array of disparate channels. If these channels are siloed, the left hand never knows what the right hand is doing. The clinical affairs team might be reviewing a critical study in a minor journal, while the sales team is hearing about "difficult implantations" from surgeons in the field, and the quality department is classifying returned devices as "no fault found."
Key Post-Market Data Inflow Channels:
- Passive Complaint Databases: Direct reports from hospital procurement, risk managers, and patients.
- Scientific Literature: Peer-reviewed studies, case reports, and independent registries (e.g., national joint registries).
- Sales Force Feedback: CRM entries, field service reports, and informal emails from sales representatives.
- Regulatory Databases: Global adverse event portals (MAUDE, BfArM, MHRA) tracking competitor devices with similar designs.
- Active Clinical Studies: Post-approval studies, registry participations, and investigator-initiated trials.
When these channels are analyzed collectively, a clear, unmistakable safety signal often emerges months or even years before the company officially acknowledges a problem. The threshold of actionable knowledge is crossed the moment a statistically significant deviation from the baseline safety profile is detectable by a competent epidemiologist. By using biostatisticians to analyze the company’s internal databases retrospectively, you can prove that if the company had applied standard signal detection algorithms to their own data, they would have seen the hazard light flashing red long before the plaintiff was injured.
Building the Plaintiff's Case: Evidentiary Goldmines
To build a winning case against a multi-billion-dollar manufacturer, you cannot rely on emotional appeals or general assertions of corporate greed. You must beat them with their own data. The modern corporate environment is highly documented; every decision, every risk assessment, and every ignored warning leaves a digital footprint. Your objective during discovery is to gain access to these internal systems and extract the evidence that proves the corporation’s post-market surveillance was a hollow shell.
This process requires a deep, technical understanding of how medical device companies operate internally. You are not just looking for a single email where an executive says, "Let's ignore this safety issue"—though those do occasionally exist. Instead, you are looking to document a systemic pattern of behavior. You want to show a culture where safety data is systematically minimized, where budgets for post-market investigations are cut while marketing budgets expand, and where internal whistleblowers are sidelined or ignored.
+-----------------------------------------------------------------------------+
| INSIDER NOTE |
| During discovery, do not just ask for "complaint files." Ask for the raw |
| database export of the Quality Management System (QMS), including the SQL |
| schema and transactional metadata. This prevents the defense from filtering |
| out "non-complaint" inquiries or "service requests" that actually contain |
| critical safety data regarding device failures. |
+-----------------------------------------------------------------------------+
When you successfully obtain this raw data, the narrative changes. You are no longer arguing about opinions; you are presenting facts. You can show the jury a timeline where the company’s internal engineers were raising red flags in internal memos, while the public-facing marketing materials continued to boast about the product's flawless track record. This stark contrast between internal reality and external representation is the most powerful weapon in a plaintiff’s arsenal.
Mining the Quality Management System (QMS)
The Quality Management System (QMS) is the nervous system of a medical device manufacturer. It is where all processes related to product quality, safety, and regulatory compliance are housed. Within the QMS, the Corrective and Preventive Action (CAPA) system is the most critical area for establishing liability. A CAPA is triggered when a systemic issue is identified, requiring the company to investigate the root cause and implement changes to prevent recurrence. If a company has a high rate of product failures but no open CAPAs, or if their CAPAs are kept open indefinitely without resolution, you have found a major failure in their safety process.
To effectively mine the QMS, you must request a specific set of documents that corporate defense attorneys desperately want to keep under wraps. These documents provide the structural context of how the company handles safety data on a daily basis.
Essential QMS Discovery Checklist:
- The Complete CAPA Log: A chronological list of all CAPAs opened, closed, or pending, which allows you to identify when the company officially recognized systemic design or manufacturing flaws.
- Complaint File Audit Trails: The digital history of individual complaint files, showing who accessed them, what changes were made to the classification codes, and whether safety issues were downgraded to "user error."
- Health Hazard Evaluations (HHEs) / Risk Assessments: Internal documents where the company's clinical experts evaluate the risk of a reported failure and determine whether a recall or field action is necessary.
- Internal Quality Audit Reports: Self-assessments conducted by the company's internal auditors or external consultants, which frequently flag systemic deficiencies in the PMS system years before an FDA inspection.
- Engineering Change Orders (ECOs): Documentation showing quiet, rolling design modifications made to address safety issues without issuing a formal recall.
When reviewing these documents, pay close attention to the dates. You will often find a pattern where an HHE concludes that a device failure poses a "moderate to high risk of serious injury," yet the company waits twelve to eighteen months to take any corrective action. During that delay, thousands of additional devices are implanted into unsuspecting patients. This gap between the realization of risk and the execution of corrective action is the classic definition of negligence.
The Signal Detection Failure
In the modern era of big data, a manufacturer cannot claim they were overwhelmed by the volume of information. Signal detection is a highly developed scientific discipline that uses statistical algorithms to identify safety trends in massive datasets. In pharmacovigilance and device safety, techniques like disproportionality analysis (calculating Proportional Reporting Ratios or Reporting Odds Ratios) are standard practice. If a company is not performing these basic statistical analyses on their complaint database, they are actively choosing to remain blind to emerging hazards.
I remember reviewing a case where the manufacturer claimed that a 2% failure rate for an implantable lead was "acceptable and expected." However, when we hired an independent biostatistician to run a simple cumulative summation (CUSUM) analysis on their raw complaint data, we discovered that a highly specific failure mode—insulation degradation—had spiked dramatically in a specific manufacturing lot. The signal was statistically significant eighteen months before the company issued a safety alert. For those eighteen months, patients were receiving a device that was statistically destined to fail, simply because the company’s quality department was looking at flat Excel sheets instead of running standard signal detection algorithms.
+-----------------------------------------------------------------------------+
| PRO-TIP |
| When deposing the head of Quality Assurance or Post-Market Surveillance, |
| ask them to define "disproportionality analysis" or "statistical signal |
| detection." Many mid-sized companies do not employ a single statistician |
| in their PMS departments. Exposing this lack of basic scientific expertise |
| to a jury completely dismantles their claim of being a "highly scientific" |
| medical company. |
+-----------------------------------------------------------------------------+
To establish liability on this front, you must show that the industry standard for signal detection was well-established and technologically feasible. If competitor companies or regulatory bodies were using these tools to identify similar risks, the defendant’s failure to do so is a clear departure from the standard of care. You must frame this not as an innocent technical oversight, but as a deliberate choice to avoid finding problems that would hurt their bottom line.
Strategic Litigation Pathways: From Negligence to Punitive Damages
Once you have gathered the evidentiary building blocks, you must assemble them into a cohesive, legally sound litigation strategy. This is not just about survival; it is about building a case that can withstand the inevitable motions to dismiss and summary judgment challenges. Your legal theories must be integrated, with each claim reinforcing the others.
The strategic pathway begins with establishing a strong foundation of ordinary negligence, but it must not stop there. If the evidence supports it, you must pave the way for punitive damages. To do this, you must elevate the corporate conduct from mere carelessness to a conscious, reckless disregard for human life. This requires proving that the company knew their failure to surveil was actively placing patients in harm's way and chose to maintain that state of ignorance because it was highly profitable.
Overcoming Federal Preemption (The Riegel Barrier)
For any attorney litigating medical device cases in the United States, federal preemption is the ultimate obstacle. Under the Supreme Court's ruling in Riegel v. Medtronic, Inc. (2008), state-law tort claims challenging the safety or effectiveness of Class III medical devices that received pre-market approval (PMA) from the FDA are expressly preempted. This ruling effectively created a shield of immunity for manufacturers of the most dangerous, high-risk devices, leaving injured patients with virtually no legal recourse under traditional design or manufacturing defect theories.
However, there is a narrow path through this barrier: the "parallel claim." To survive preemption, a plaintiff's state-law claim must be based on a duty that "parallels" a federal requirement under the Food, Drug, and Cosmetic Act (FDCA). The claim cannot impose any requirements that are "different from, or in addition to" federal rules, but it can seek damages for injuries caused by the manufacturer’s failure to comply with those very same federal rules.
+-----------------------------------------------------------------------------+
| PRO-TIP |
| To survive a motion to dismiss based on Riegel preemption, draft your |
| complaint with extreme specificity. Do not just allege a general "failure |
| to warn." Specifically allege that the manufacturer violated 21 CFR |
| 803.50 by failing to report adverse events to the FDA, and that this |
| violation directly caused a lack of information that misled your client's |
| implanting surgeon. This links the state-law negligence claim directly to a |
| federal violation, creating a valid parallel claim. |
+-----------------------------------------------------------------------------+
This is where inadequate post-market surveillance becomes the central battleground of the entire litigation. While a design defect claim is almost always preempted for PMA devices, a claim that the manufacturer failed to report adverse events to the FDA—in direct violation of federal Medical Device Reporting (MDR) regulations—is a classic parallel claim. If the manufacturer failed to report adverse events, they deprived the FDA (and by extension, the medical community) of the information necessary to update the device's labeling or issue a recall. By focusing your case on these post-market reporting violations, you can bypass the preemption defense and keep your client’s case in court.
Proving Causation through Delayed Action
Even the most egregious corporate misconduct is legally irrelevant if you cannot prove that it directly caused the plaintiff's injury. In post-market surveillance litigation, establishing causation requires proving a negative: If the company had conducted proper surveillance and acted on the signals, the plaintiff would not have been injured. This is often referred to as the "but-for" causation chain, and it requires a meticulous, step-by-step reconstruction of the clinical decision-making process.
To build this chain, you must focus on the concept of the "delayed recall" or "delayed warning." You must demonstrate to the jury that if the manufacturer had acted reasonably, they would have issued a safety alert, updated the product label, or initiated a voluntary recall at a specific point in time. You then show that the plaintiff’s surgery occurred after that date.
+-----------------------------------------------------------------------------+
| INSIDER NOTE |
| When deposing the plaintiff’s implanting surgeon, do not ask: "Would you |
| have used this device if you knew it was defective?" This invites a defensive|
| response. Instead, ask: "If the manufacturer had issued a safety alert in |
| January stating that this device had a five-fold increased risk of early |
| failure, would that information have changed your patient counseling and |
| surgical planning?" This reframes the issue around the surgeon's right to |
| make an informed clinical decision. |
+-----------------------------------------------------------------------------+
This approach connects the corporate data failure directly to the patient's physical suffering. You are showing that the company's failure to analyze their own data stripped the surgeon of their role as an informed intermediary. The surgeon was operating in the dark, relying on outdated, overly optimistic safety profiles provided by the manufacturer, while the company’s internal databases were already warning of the impending failure. This informational gap is the direct, legal cause of the patient’s injury.
Corporate Defense Tactics and How to Dismantle Them
Corporate defense firms do not defend these cases by playing nice; they use a highly sophisticated, well-funded playbook designed to confuse juries, exhaust plaintiffs' resources, and shift the blame to anyone else. If you do not anticipate these moves, your case will be dismantled before you ever reach trial.
To win, you must understand their tactics better than they do. You must expect their attempts to redirect the focus of the trial away from their own corporate behavior and onto the clinical decisions of the treating physician or the lifestyle choices of the patient. By preparing for these defenses from day one of discovery, you can turn their own arguments against them.
The "User Error" Smoke Screen
The single most common defense in medical device litigation is to blame the surgeon. The defense will hire expensive, credentialed experts to review the surgical notes and find any minor deviation from the manufacturer's "Instructions for Use" (IFU). They will argue that the device didn't fail because of a design flaw or a lack of monitoring, but because the surgeon implanted it at the wrong angle, used the wrong tool, or selected an inappropriate patient. This is the "user error" smoke screen.
To dismantle this defense, you must shift the focus back to the principles of human factors engineering. Under both FDA guidelines and international standards (such as IEC 62366), manufacturers are required to design devices that minimize the risk of user error. If a device is designed in a way that makes it highly sensitive to minor surgical variations, that is a design defect, not user error. Furthermore, if the manufacturer’s post-market surveillance system was receiving numerous reports of "user error" from different surgeons across the country, they had a duty to recognize that this was a systemic design issue, not a series of isolated surgical mistakes.
Steps to Dismantle the "User Error" Defense:
- Establish the Pattern: Show that the same "user error" was reported by dozens of different surgeons who had no connection to each other, proving the issue is systemic.
- Examine Training Materials: Review the company’s sales training records to show that their own reps were training surgeons to implant the device in the exact manner now being criticized.
- Analyze Human Factors Testing: Force the company to produce their pre-market human factors usability studies to show they knew the device was prone to this specific error.
- Depose Sales Reps: Depose the field sales representative who was present in the operating room during the plaintiff's surgery; they will often admit the surgeon performed the procedure beautifully.
- Expose the Lack of Action: Show that despite knowing surgeons were struggling with this specific step, the company failed to update their training, modify the IFU, or redesign the tool.
By systematically executing these steps, you transform the defense's argument into a major liability for them. You show the jury that the manufacturer knew their device was difficult to use and prone to error, yet they chose to blame the doctors rather than fixing the product or providing better training. This shift in narrative turns a technical defense into a compelling story of corporate deflection and unaccountability.
The "State-of-the-Art" Defense
Another common corporate defense is the "state-of-the-art" argument. The manufacturer will claim that at the time the product was sold, the scientific knowledge and technology available did not allow them to detect or prevent the risk. They will present themselves as pioneers operating at the very edge of scientific discovery, arguing that the patient's injury was an unpredictable, tragic side effect of cutting-edge technology that no one could have foreseen.
This defense relies on a highly selective reading of scientific history. To dismantle it, you must conduct a thorough, independent review of the scientific literature and industry standards that existed at the time. You will almost always find that the "unforeseeable" risk was actually discussed in academic journals, competitor patents, or veterinary studies years before the defendant’s device was even designed.
+-----------------------------------------------------------------------------+
| PRO-TIP |
| During discovery, request the search history of the company’s internal |
| medical library and the literature monitoring alerts set up by their |
| regulatory affairs team. You will often find that their own librarians |
| were flagging and downloading articles about these "unforeseeable" risks |
| while the marketing team was drafting press releases claiming the safety |
| concerns were unproven. |
+-----------------------------------------------------------------------------+
When you present this evidence, the "state-of-the-art" defense collapses. You show that the science was there, the warnings were there, and the competitors were paying attention. The defendant was not a pioneer operating at the limits of human knowledge; they were simply ignoring the science because acknowledging it would have delayed their product launch or forced an expensive redesign.
Best Practices for Corporate Counsel: Shifting from Reactive to Proactive
While much of this guide focuses on how to establish liability, there is a powerful lesson here for corporate counsel and quality executives who want to avoid finding themselves on the receiving end of these lawsuits. The current, reactive approach to post-market surveillance is a ticking financial time bomb. The cost of defending a multi-district litigation (MDL), coupled with the devastating impact on brand reputation and stock value, dwarfs the cost of maintaining a world-class post-market surveillance system.
To protect both patients and the corporation, counsel must lead a cultural shift from passive, defensive compliance to proactive, safety-driven vigilance. This is not just an ethical obligation; it is a sound business strategy. By identifying and addressing safety signals early, companies can implement targeted, orderly product updates or voluntary recalls before a problem escalates into a public health crisis and a legal catastrophe.
+-----------------------------------------------------------------------------+
| INSIDER NOTE |
| Corporate counsel must establish a truly independent safety review board |
| within the company that has the authority to halt manufacturing or trigger |
| a recall without approval from commercial or marketing executives. If the |
| safety team has to ask permission from the sales team to protect patients, |
| your corporate governance model is a liability goldmine for plaintiffs. |
+-----------------------------------------------------------------------------+
This proactive model requires a fundamental restructuring of how post-market data is handled internally. It means breaking down the silos between clinical, quality, engineering, and sales departments. It means investing in modern, AI-driven signal detection tools and employing qualified epidemiologists and biostatisticians to monitor product performance. Most importantly, it requires a culture where raising a safety concern is celebrated as an act of corporate stewardship, rather than silenced as a threat to quarterly earnings.
Conclusion: The Ethical Imperative of Post-Market Vigilance
As we look to the future of medical technology—with the rise of artificial intelligence, software-as-a-medical-device (SaMD), and highly personalized implants—the importance of post-market surveillance will only grow. These complex, dynamic technologies cannot be fully validated in a
[Field Report] Inside An Initial Legal Consultation: What Happens When You Call A Surgical Error AttorneyPost-market Surveillance Requirements in ISO 14971 by Let's Talk Risk
Title: Post-market Surveillance Requirements in ISO 14971
Channel: Let's Talk Risk
[Consumer Alert] Signs That Your Post-Medication Health Issues Were Caused By Defective Formulations
3 Steps to Ensure Data Quality for Post-Market Surveillance by Let's Talk Risk
Title: 3 Steps to Ensure Data Quality for Post-Market Surveillance
Channel: Let's Talk Risk
Pengawasan pasca-pemasaran sebagai persyaratan alat kesehatan di UE by Medical Device HQ
Title: Pengawasan pasca-pemasaran sebagai persyaratan alat kesehatan di UE
Channel: Medical Device HQ
